Accordingly, GLP-1 has attracted considerable attention for developing anti-obesity or type 2 diabetes drugs using GLP-1 receptor agonists [35,36,37,38]. This evidence concerns the gene GLP1R and obesity due to melanocortin 4 receptor deficiency.